Journal
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
Volume 32, Issue 2, Pages 106-114Publisher
EDICIONES DOYMA S A
DOI: 10.1016/j.eimc.2012.11.012
Keywords
Adjuvants; Vaccines; Efficacy; Toxicity
Categories
Ask authors/readers for more resources
To achieve effective and safe vaccines for the prevention of not yet controlled or re-emergent infectious diseases, one of the more importance aspects is to have immunological adjuvants that allow inducing a protective immune response with an appropriate safety profile. Since 1926 the aluminium compounds have been used as adjuvants for human vaccines, and only in the last 10 years some new products have been registered. Although there an enormous quantity of proposed candidates, the toxicity is the main factor that has limited their introduction into the clinic. In this work the mechanism of action are updated, and the toxicity of the immunological adjuvants are revised, especially those that have obtained clinical approval or are close to getting it. (C) 2012 Elsevier Espana, S.L. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available